Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 15/20 | 0.52 |
| ▸ | CA1 | P00915 | 14/20 | 0.52 |
| ▸ | CA2 | P00918 | 14/20 | 0.52 |
| ▸ | CA12 | O43570 | 6/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.44 |
| ▸ | ELF3 | P78545 | 1/20 | 0.44 |
| ▸ | MED23 | Q9ULK4 | 1/20 | 0.44 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18633954 | 0.91 | CA9 (0.63) | CA9CA1CA2CA12USP2 | |
| SCHEMBL10205352 | 0.87 | POLB (0.47) | CA9CA1CA2CA12USP2 | |
| SCHEMBL10014172 | 0.87 | CA9 (0.56) | CA9CA1CA2CA12USP2 | |
| SCHEMBL19788026 | 0.83 | CA9 (0.62) | CA9CA1CA2CA12USP2 | |
| SCHEMBL12231697 | 0.82 | CA9 (0.75) | CA9CA1CA2CA12USP2 | |
| SCHEMBL16181495 | 0.81 | CA9 (0.67) | CA9CA1CA2CA12USP2 | |
| SCHEMBL14089620 | 0.81 | CA9 (0.55) | CA9CA1CA2CA12USP2 | |
| SCHEMBL12637546 | 0.81 | USP2 (0.57) | CA9CA1CA2CA12USP2 | |
| SCHEMBL14852664 | 0.80 | CA9 (0.58) | CA9CA1CA2CA12USP2 | |
| SCHEMBL23762521 | 0.79 | CA9 (0.66) | CA9CA1CA2CA12USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047692-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | INVITROGEN CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047692-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | MGAM, LCT, GAA | CA9 381/4885CA1 913/4885CA2 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.